2006
DOI: 10.1111/j.1365-2982.2006.00792.x
|View full text |Cite
|
Sign up to set email alerts
|

Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse

Abstract: Serotonin-selective reuptake transporter (SERT) expression is decreased in animal models of intestinal inflammation and in individuals with inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS), and it is possible that resultant changes in intestinal serotonin signalling contribute to the manifestation of clinical features associated with these disorders. The objective of this investigation was to determine whether inhibition of SERT function leads to changes in gut motility and sensitivity. Mice … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
60
0
2

Year Published

2007
2007
2018
2018

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 87 publications
(67 citation statements)
references
References 45 publications
5
60
0
2
Order By: Relevance
“…Also, transgenic mice lacking SERT frequently exhibit diarrhea associated with watery stools interspersed with periods of constipation (5). Additionally, SERT inhibitors decrease guinea pig colonic motility (21,36) as well as mouse intestinal transit time and fecal output (6).…”
mentioning
confidence: 99%
“…Also, transgenic mice lacking SERT frequently exhibit diarrhea associated with watery stools interspersed with periods of constipation (5). Additionally, SERT inhibitors decrease guinea pig colonic motility (21,36) as well as mouse intestinal transit time and fecal output (6).…”
mentioning
confidence: 99%
“…SERT expression is reduced in the inflamed and in the healing colonic mucosa of UC patients, thereby increasing 5-HT levels [25,58]. Furthermore, deletion of SERT increases the severity of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in mice [59] and mice treated with the SERT inhibitor paroxetine presented alterations in GI motility and sensitivity [60]. Interestingly, the regulatory cytokine transforming growth factor-beta 1 (TGF-β1) was recently shown to stimulate SERT function suggesting a novel neuro-immune therapeutic strategy to treat GI disorders [61].…”
Section: The Intestinal Serotonergic Systemmentioning
confidence: 99%
“…Desse percentual, aproximadamente 90% é sintetizado em células enteroendócrinas, um subtipo de células enterocromafins, e 10% nos neurônios entéricos. Essa 5-HT, presente no trato gastrintestinal age como um neurotransmissor das funções sensório-motoras gastrintestinais (KIM; CAMILLERI, 2000;COATES et al, 2006;GERSHON;TACK, 2007).…”
Section: Desenvolvimento Serotoninaunclassified